abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) saw a large increase in short interest in the month of August. As of August 31st, there was short interest totaling 77,400 shares, an increase of 151.3% from the August 15th total of 30,800 shares. Currently, 0.3% of the company's shares are sold short. Based on an average daily volume of 109,100 shares, the days-to-cover ratio is presently 0.7 days. Based on an average daily volume of 109,100 shares, the days-to-cover ratio is presently 0.7 days. Currently, 0.3% of the company's shares are sold short.
Insider Buying and Selling
In related news, major shareholder Saba Capital Management, L.P. sold 23,723 shares of abrdn Life Sciences Investors stock in a transaction on Friday, August 29th. The shares were sold at an average price of $13.89, for a total value of $329,512.47. Following the transaction, the insider owned 2,982,706 shares in the company, valued at $41,429,786.34. This trade represents a 0.79% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In the last 90 days, insiders have sold 66,758 shares of company stock valued at $937,551. 10.06% of the stock is owned by company insiders.
Hedge Funds Weigh In On abrdn Life Sciences Investors
A number of hedge funds have recently modified their holdings of the company. Penserra Capital Management LLC increased its position in shares of abrdn Life Sciences Investors by 3.0% in the second quarter. Penserra Capital Management LLC now owns 769,657 shares of the company's stock valued at $9,859,000 after acquiring an additional 22,736 shares during the period. Needham Investment Management LLC increased its position in shares of abrdn Life Sciences Investors by 7.4% in the first quarter. Needham Investment Management LLC now owns 378,654 shares of the company's stock valued at $4,805,000 after acquiring an additional 25,935 shares during the period. Raymond James Financial Inc. increased its position in shares of abrdn Life Sciences Investors by 20.3% in the second quarter. Raymond James Financial Inc. now owns 375,960 shares of the company's stock valued at $4,816,000 after acquiring an additional 63,429 shares during the period. Flagship Harbor Advisors LLC increased its position in shares of abrdn Life Sciences Investors by 0.3% in the second quarter. Flagship Harbor Advisors LLC now owns 341,959 shares of the company's stock valued at $4,380,000 after acquiring an additional 1,082 shares during the period. Finally, LPL Financial LLC increased its position in shares of abrdn Life Sciences Investors by 14.4% in the first quarter. LPL Financial LLC now owns 328,402 shares of the company's stock valued at $4,167,000 after acquiring an additional 41,307 shares during the period. Hedge funds and other institutional investors own 32.21% of the company's stock.
abrdn Life Sciences Investors Price Performance
NYSE:HQL traded up $0.18 during trading hours on Thursday, reaching $14.13. The company's stock had a trading volume of 113,713 shares, compared to its average volume of 95,209. The firm has a 50-day simple moving average of $13.63 and a 200-day simple moving average of $12.90. abrdn Life Sciences Investors has a 1 year low of $10.55 and a 1 year high of $15.68.
abrdn Life Sciences Investors Cuts Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Friday, August 22nd will be given a $0.42 dividend. The ex-dividend date is Friday, August 22nd. This represents a $1.68 dividend on an annualized basis and a dividend yield of 11.9%.
abrdn Life Sciences Investors Company Profile
(
Get Free Report)
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.
See Also
Before you consider abrdn Life Sciences Investors, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and abrdn Life Sciences Investors wasn't on the list.
While abrdn Life Sciences Investors currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here

We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.